- Home
- ONCY vs WEA Comparison
ONCY vs WEA Comparison
Compare ONCY & WEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ONCY | WEA |
|---|---|---|
| Founded | 1998 | 2002 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.3M | 125.4M |
| IPO Year | 2002 | N/A |
Fundamental Metrics
Financial Performance| Metric | ONCY | WEA |
|---|---|---|
| Price | $0.83 | $10.58 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $7.33 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 17.4K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.87% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,505.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.77 | $10.30 |
| 52 Week High | $1.51 | $11.44 |
Technical Indicators
Market Signals| Indicator | ONCY | WEA |
|---|---|---|
| Relative Strength Index (RSI) | 43.20 | 46.67 |
| Support Level | $0.81 | $10.48 |
| Resistance Level | $1.06 | $10.72 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 15.26 | 23.57 |
Price Performance
Historical ComparisonAbout ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
About WEA Western Asset Bond Fund Share of Beneficial Interest
Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The fund invests in bonds of companies operating in different sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.